Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma

NCT01780662 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

46

Enrollment

NIH

Sponsor class

Conditions

Recurrent Adult Hodgkin Lymphoma
Recurrent Childhood Hodgkin Lymphoma
Refractory Childhood Hodgkin Lymphoma

Interventions

DRUG: Brentuximab Vedotin
DRUG: Gemcitabine Hydrochloride

Sponsor

National Cancer Institute (NCI)